Readystate Asset Management LP Purchases New Holdings in Nektar Therapeutics $NKTR

Posted by Brian Himes on Sep 7th, 2026

Readystate Asset Management LP purchased a new position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 85,110 shares of the biopharmaceutical company’s stock, valued at approximately $5,942,000.

A number of other hedge funds have also recently added to or reduced their stakes in NKTR. BNP Paribas Financial Markets grew its holdings in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares in the last quarter. KBC Group NV acquired a new position in Nektar Therapeutics in the first quarter valued at about $52,000. Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the second quarter valued at about $65,000. State of Wyoming bought a new stake in Nektar Therapeutics during the first quarter worth about $67,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Nektar Therapeutics during the first quarter worth about $68,000. Institutional investors own 75.88% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on NKTR shares. Wall Street Zen raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. TD Cowen upgraded shares of Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush decreased their price objective on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Nektar Therapeutics in a research report on Friday, August 21st. They set a “neutral” rating and a $65.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $141.50.

Get Our Latest Research Report on Nektar Therapeutics

Insider Activity at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 5,681 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total value of $397,670.00. Following the completion of the transaction, the insider owned 9,756 shares of the company’s stock, valued at $682,920. This represents a 36.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the sale, the chief executive officer owned 54,627 shares in the company, valued at $3,932,051.46. This represents a 0.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 21,823 shares of company stock worth $1,380,558 over the last ninety days. 2.50% of the stock is currently owned by insiders.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $74.19 on Monday. Nektar Therapeutics has a 12-month low of $33.40 and a 12-month high of $109.00. The business’s 50-day moving average price is $71.81 and its two-hundred day moving average price is $72.09. The stock has a market cap of $2.53 billion, a PE ratio of -11.07 and a beta of 1.14.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) EPS for the quarter, topping the consensus estimate of ($1.97) by $0.74. The firm had revenue of $10.13 million during the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. As a group, analysts expect that Nektar Therapeutics will post -8.28 earnings per share for the current year.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

Positive Sentiment: Zacks raised its estimated 2026 loss to $8.58 per share from $10.59, including improved forecasts for third-quarter 2026 ($2.45 loss versus $3.05 previously) and fourth-quarter 2026 ($3.07 loss versus $3.26 previously). Nektar Therapeutics analyst estimates
Positive Sentiment: The firm also modestly improved its first-quarter 2027 EPS estimate to a $3.17 loss from a $3.41 loss, suggesting some expected improvement in selected periods.
Neutral Sentiment: Despite the revisions, Nektar remains expected to report substantial losses: the current consensus for the company’s full-year earnings is a loss of $8.51 per share, while the stock’s negative earnings profile underscores its dependence on clinical and pipeline progress rather than current profitability.
Negative Sentiment: Zacks sharply reduced its 2027 outlook, increasing the projected full-year loss to $16.15 per share from $13.28. Estimates were also lowered for the second quarter of 2027, third quarter of 2027, and fourth quarter of 2027.
Negative Sentiment: Longer-term expectations deteriorated further: the projected 2028 loss widened to $17.77 per share from $14.02, with estimates lowered for the first and second quarters of 2028 as well as the second quarter of 2028. These revisions imply greater anticipated cash burn or operating costs and are likely weighing on investor sentiment.

Nektar Therapeutics Company Profile

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.